Speaker: Professor Steven R Garfin, Distinguished Professor, Department of Orthopaedic Surgery and Interim Dean, University of California San Diego School of Medicine, USA

Clinical research studies funded by the industry are often looked at as tainted/biased, as they are focused on the industry’s proposed new treatment. If not for the industry, who would fund new treatment options, and who would perform them besides the developer and clinicians selected for the Scientific Advisory Board and clinical trials? The U.S. Food and Drug Administration (FDA) sets the protocol, the “company” funds it, and the researchers follow the “rules” to get the data accepted, published and funded by insurance. This does not differ a lot from U.S. National Institutes of Health (NIH) funding, where future funding depends on positive research results.

Registration & breakfast at 7.10am, talk begins at 7.40am.